Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease

Insights

Macrophage migration inhibitory factor (MIF) drives cyst growth in autosomal dominant polycystic kidney disease (ADPKD). Inhibiting MIF or its associated inflammation, including TNF-α, significantly delays cyst development in ADPKD models.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) involves cyst formation, inflammation, and fibrosis.
  • The precise role of inflammatory factors like macrophages in ADPKD progression remains unclear.

Purpose of the Study:

  • To investigate the role of macrophage migration inhibitory factor (MIF) in ADPKD pathogenesis.
  • To explore MIF as a potential therapeutic target for ADPKD.

Main Methods:

  • Upregulation and localization of MIF in murine and human ADPKD kidneys.
  • Assessing MIF's effects on cystic epithelial cell proliferation, apoptosis, and metabolism.
  • Evaluating the impact of Mif deletion or pharmacologic inhibition on cyst growth in murine ADPKD models.
  • Analyzing the interplay between MIF, macrophages, MCP-1, and TNF-α.

Main Results:

  • MIF is upregulated in ADPKD kidneys and promotes cyst growth by activating proliferative pathways (ERK, mTOR, Rb/E2F) and increasing glucose metabolism.
  • MIF regulates apoptosis via p53-dependent signaling and is crucial for macrophage recruitment and retention in cystic kidneys.
  • Mif deletion or inhibition significantly delays cyst growth in ADPKD models.
  • A positive feedback loop exists between TNF-α and MIF, with MIF exacerbating TNF-α expression.

Conclusions:

  • MIF acts as a central, upstream regulator of ADPKD pathogenesis.
  • Targeting MIF and associated inflammatory pathways presents a promising therapeutic strategy for ADPKD.

Related Concept Videos